Posaconazole mono- or combination therapy for treatment of murine zygomycosis

Antimicrob Agents Chemother. 2009 Feb;53(2):772-5. doi: 10.1128/AAC.01124-08. Epub 2008 Oct 20.

Abstract

We compared the efficacy of combination posaconazole-liposomal amphotericin B (LAmB) therapy to monotherapy with either drug in diabetic ketoacidotic or neutropenic mice with disseminated zygomycosis caused by Rhizopus oryzae. Combination therapy was no better than LAmB alone, and posaconazole monotherapy did not improve survival or reduce fungal burden versus placebo.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Animals
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / therapeutic use*
  • Brain / microbiology
  • Brain / pathology
  • Diabetic Ketoacidosis / complications
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Kidney / microbiology
  • Kidney / pathology
  • Liposomes
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Neutropenia / complications
  • Rhizopus
  • Triazoles / administration & dosage
  • Triazoles / therapeutic use*
  • Zygomycosis / drug therapy*
  • Zygomycosis / microbiology

Substances

  • Antifungal Agents
  • Drug Combinations
  • Liposomes
  • Triazoles
  • posaconazole
  • Amphotericin B